SMS. Monjanel-Mouterde

S. Monjanel-Mouterde

*This is an algorithmically generated author record based on publicly available information.

S. Monjanel-Mouterde has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lack of toxicity of hydroethanolic extract from Mitragyna inermis (Willd.) O. Kuntze by gavage in the rat

    by S. Monjanel-Mouterde, F. Traoré, M. Gasquet, F. Dodero, F. Delmas, J.F. Ikoli, A.M. Lorec, V. Chamlian, H. Portugal, G. Balansard, et al.


  • Open Access

    Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback

    by S. Monjanel-Mouterde, J. Ciccolini, D. Bagarry, M. Zonta-David, F. Duffaud, R. Favre, A. Durand

    Objective: A Bayesian population pharmacokinetics study of data from routine therapeutic drug monitoring cisplatin during a 5-day infusion of cisplatin. Methods: A total of 95 kinetics data sets (5...


  • Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer

    by S. Monjanel-Mouterde, C. Lejeune, J. Ciccolini, N. Merite, D. Hadjaj, P. Bonnier, P. Piana, A. Durand

    Background: Methotrexate (MTX) infusions may induce severe side‐effects, and alkaline hydration along with folinic acid rescue is a common way to reduce such toxic risks. The purpose of this study w...


  • Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.

    by S Monjanel-Mouterde, C Frenay, J Catalin, C Boutin, A Durand, P Astoul

    We determined the toxicity and pharmacokinetics of high-dose intrapleural cisplatin (CDDP) as a treatment of malignant pleural effusions (MPE). Fourteen patients with MPE were enrolled in this study. After complete drainage of the fluid, a catheter was inserted into the pleural cavity during a thoracoscopy. CDDP (300 mg) was administered via the catheter in a 6-h infusion. Peak levels, the areas under the concentration curve (AUC), and drug half-lives were measured in pleural fluid and plasma samples collected at 0 (baseline), 6, and 24 h as well as 4, 14, and 21 days after intrapleural administration. The dosage of CDDP ranged from 153 to 203 mg/m2. The time interval between infusion was prolonged until a maximum of 109 days. Only 7/40 infusions were associated with adverse effects in 4 patients (18%). Residual concentrations in pleural fluid (0.66+/-0.07 microgram /ml) were three-fold higher than in plasma (0.13+/-0.07 microgram/ml). In pleural fluid, maximal concentration (Cmax) varied from 19 to 900 microgram/ml and in plasma from 0.34 to 3.65 microgram/ml. AUC in plasma during the three courses was 112+/-49 microgram/ml/d. The T1/2 was 31+/-33 days higher than that previously reported after intravenous administration (8-15 days). Although intrapleural CDDP has the potential advantage of treating the underlying malignancy in addition to controlling the malignant effusion with a good tolerance, it cannot be recommended for the standard control of malignant pleural effusion. Indeed we observed a great variability of intrapleural CDDP concentration depending on the extent of pleural invasion and plasma diffusion. Further studies are needed to determine the value of high-dose intrapleural CDDP for the treatment of MPE.


    • 1 July 1998
      • Vol. 25  (7) , 1276-81

    Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.

    by S Monjanel-Mouterde, P Lafforgue, A Blanc, J Catalin, P C Aquaviva, A Durand

    To determine a pharmacokinetic procedure (Bayesian method) for estimation of methotrexate (MTX) clearance, using only 2 blood samples, in outpatients with rheumatoid arthritis treated with low dose intramuscular (i.m.) MTX. Population pharmacokinetic parameters were obtained by the weighted least squares (WLSQ) method in plasma samples from 14 patients with rheumatoid arthritis (RA). In each patient, 11 samples were measured by fluorescence polarization immunoassay, at Time 0, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, and 24 h after i.m. administration. These measures were validated by pharmacokinetic studies in 20 other patients with RA. Individual total body clearance of MTX was calculated using only 2 plasma samples (at 0.5 and 2 h after i.m. injection) by the Bayesian method using the population pharmacokinetic parameters. The clearance measures obtained by the Bayesian method were compared with those obtained by the WLSQ method. The pharmacokinetic variables (clearance, half-life, area under the curve) of 14 patients were determined, as well as the covariance and the mean values necessary to apply the Bayesian method. No significant difference was found between clearance values obtained by the Bayesian method compared to the WLSQ method, confirming the validity of the Bayesian values. The present population pharmacokinetic parameters allowed the determination of individual clearance of MTX with only 2 plasma samples (0.5 and 2 h after administration) in patients treated with low dose im MTX. Individual clearance is used to modulate MTX administration in patients presenting adverse reactions in spite of good clinical response. Individual determination of MTX pharmacokinetics in patients at risk for adverse MTX reactions could be useful for adjustment of the drug regimen.


  • Pharmacokinetics of Tropatepine in Healthy Volunteers

    by H. Bun, S. Monjanel-Mouterde, C. Audebert, M. Vincent Du Laurier, A. Durand, J. P. Cano


    • 1 February 1993
      • Vol. 20  (2) , 263-7

    Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients.

    by P Lafforgue, S Monjanel-Mouterde, A Durand, J Catalin, P C Acquaviva

    A study of methotrexate (MTX) pharmacokinetics with and without prednisolone was performed in 33 patients with rheumatoid arthritis. Ten mg im MTX were given on Day 0; patients were divided into 3 groups of 11 persons: Group 1: no corticosteroid; Group 2: prednisolone 15 mg/day per os from D -3 on; Group 3: patients continuing longterm prednisolone treatment (15 mg/day). Groups 1 and 2 were randomized. MTX plasma concentrations were measured at T 0, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12 and 24 h using fluorescence polarization immunoassay (TDx Abbott). There was no difference between MTX pharmacokinetics of Groups 1 and 2. Area under the curve (AUC), Cmax and residual concentration at 24th h were higher, while total body and renal MTX clearances were lower in Group 3 vs Groups 1 and 2. Only the differences in AUC and total clearance were significant (p < 0.01 and p < 0.05). Tmax and terminal half-life did not differ. Our data suggest a possible influence of prednisolone on MTX pharmacokinetics in longstanding steroid treated patients. The pharmacological processes that might be involved are discussed.